Cipla Share Price Falls 2.4%; Provides Update on Lanreotide Supply

Cipla share price (NSE: CIPLA) remained in focus on Friday, January 16, 2026, after the stock declined sharply in early trade. The shares were trading at ₹1,400, down ₹34.50 or 2.41% from the previous close of ₹1,434.50. The stock opened at ₹1,379 and touched an intraday high of ₹1,402 and a low of ₹1,367.20 amid concerns over supply of a key product in the US market.

Update on Lanreotide Supply

The company issued a detailed clarification regarding Lanreotide Injection, one of its top three products in the United States. Pharmathen International S.A., which is the exclusive manufacturer and supplier of this product to Cipla USA Inc., was inspected by the US Food and Drug Administration at its Rodopi, Greece facility between November 10 and November 21, 2025.

USFDA Form 483 Observations

Following the inspection, the USFDA issued nine observations in Form 483. A redacted version of the document was made public on January 7, 2026, after which several media reports emerged leading to significant volatility in Cipla’s share price. The company stated that it has been in active discussions with Pharmathen to assess the situation.

Temporary Pause in Production

Cipla informed that production at the facility has been temporarily paused to support remediation measures. As a result, re-supply of Lanreotide to the US market is now expected to resume only in the first half of FY2026-27. Until manufacturing restarts, the product will remain in limited supply and will be released only after necessary quality clearances.

Company’s Response

Cipla said it is closely monitoring the development and is working with its partner to restore normal supplies at the earliest. The company reiterated its commitment to maintaining compliance and ensuring reliable availability of the product, which is a critical therapy for patients in the US.

Also Read: Cipla Share Price Falls Nearly 5% After USFDA Flags Compliance Issues at Key Partner!

Conclusion

The update on Lanreotide has created near-term uncertainty for Cipla’s US business and triggered selling pressure in the stock. However, the company’s proactive engagement with Pharmathen and focus on remediation provide visibility of eventual recovery once production resumes in the coming financial year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.